Literature DB >> 10665494

Profile of endothelial and leukocyte activation in Fabry patients.

T DeGraba1, S Azhar, F Dignat-George, E Brown, B Boutière, G Altarescu, R McCarron, R Schiffmann.   

Abstract

Fabry disease is an X-linked recessive disorder resulting in the deposition of globotriaosylceramide in numerous cell types including vascular endothelial cells. Because this disease is associated with vascular injury and a high recurrence rate of thrombotic events, measurements of factors regulating endothelium and leukocyte interaction may provide insight into the mechanisms leading to a prothrombotic state. Twenty-five patients with Fabry disease and 25 control subjects participated in the study. Plasma from all 25 Fabry patients and 15 of the 25 controls were studied for multiple endothelial factors. Leukocyte integrins were measured by flow cytometry in 21 Fabry patients and 10 controls. The concentrations of soluble intercellular adhesion molecule-1, vascular cell adhesion molecule-1, P-selectin, and plasminogen activator inhibitor were significantly higher and thrombomodulin was significantly lower in Fabry patients. Expression of the integrin CD11b on monocytes was also significantly higher in the Fabry patients. This study reveals measurable evidence for endothelium and leukocyte activation that is consistent with a prothrombotic state in Fabry patients compared with controls. Further investigations of these findings may help to understand the mechanism of stroke in Fabry disease and provide indicators (or markers) of efficacy of future therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665494

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  49 in total

Review 1.  New biotechnological and nanomedicine strategies for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2010 Mar-Apr

2.  Enhanced endothelium-dependent vasodilation in Fabry disease.

Authors:  G Altarescu; D F Moore; R Pursley; U Campia; S Goldstein; M Bryant; J A Panza; R Schiffmann
Journal:  Stroke       Date:  2001-07       Impact factor: 7.914

Review 3.  Targeted endothelial nanomedicine for common acute pathological conditions.

Authors:  Vladimir V Shuvaev; Jacob S Brenner; Vladimir R Muzykantov
Journal:  J Control Release       Date:  2015-10-03       Impact factor: 9.776

4.  Strategies for delivery of therapeutics into the central nervous system for treatment of lysosomal storage disorders.

Authors:  Silvia Muro
Journal:  Drug Deliv Transl Res       Date:  2012-06-01       Impact factor: 4.617

5.  [Fabry's disease: new therapeutic options for this lysosomal storage disorder].

Authors:  A J Grau; M Schwaninger; H H Goebel; M Beck
Journal:  Nervenarzt       Date:  2003-05-20       Impact factor: 1.214

6.  Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Authors:  Janet Hsu; Daniel Serrano; Tridib Bhowmick; Kishan Kumar; Yang Shen; Yuan Chia Kuo; Carmen Garnacho; Silvia Muro
Journal:  J Control Release       Date:  2010-11-01       Impact factor: 9.776

7.  α-galactosidase A deficiency promotes von Willebrand factor secretion in models of Fabry disease.

Authors:  Justin J Kang; Nayiri M Kaissarian; Karl C Desch; Robert J Kelly; Liming Shu; Peter F Bodary; James A Shayman
Journal:  Kidney Int       Date:  2018-11-22       Impact factor: 10.612

Review 8.  Can we use statins to prevent stroke in Fabry disease?

Authors:  J M Politei
Journal:  J Inherit Metab Dis       Date:  2009-06-02       Impact factor: 4.982

9.  Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.

Authors:  Jason Papademetriou; Carmen Garnacho; Daniel Serrano; Tridib Bhowmick; Edward H Schuchman; Silvia Muro
Journal:  J Inherit Metab Dis       Date:  2012-09-12       Impact factor: 4.982

10.  Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.

Authors:  Jin-Song Shen; Xing-Li Meng; David F Moore; Jane M Quirk; James A Shayman; Raphael Schiffmann; Christine R Kaneski
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.